Download the full presentation

Our own CTO, Lei Chen, held an award winning presentation at ESCCA 2023 in Utrecht, “Ultra-sensitive molecular MRD on flow cytometer using superRCA mutation assay”.

He explained the superRCA technology, showed data on sensitivity and performance in comparison with current methods, and showed why it matters in MRD using a patient case.

In the presentation you can see results of testing AML patients using FCM, NGS, ddPCR and Rarity Biosciences ultra-sensitive superRCA. The presentation also suggests why Flow-MRD and superRCA molecular-MRD could be a good match in AML patient monitoring.

Huge thanks to Lei and the team for crafting such a good presentation, from data generation to design and delivery.

“This is the first time we engage with the ESCCA community and so getting a “Best Oral Award” is of special importance to us, not only from the stand-point that the community finds the data of high scientific relevance, but also that they appreciate what it could mean for MRD and flow cytometry going forward.”

Alexander Kele

Director Business development

Rarity Bioscience

To get all the visuals, check out the presentation here!

Thanks to everyone who was at ESCCA and listened to the presentation.

The method is published in Nature Communication. This is the technology on which Rarity Bioscience is based and the article describes the application in Leukemia.

You can read the publication here

Share this article

Recommended articles

Rarity Bioscience at the CYTO 2024 Conference

Rarity Bioscience’s Linus Bosaeus and Lei Chen was at the CYTO 2024 Conference in Edinburgh, to present the study Ultra-sensitive Molecular MRD on Flow Cytometer using superRCA Mutation Assay, showcasing our new ultra-sensitive mutation detection technology superRCA.

Read more »

Rarity Bioscience at the Nordic Precision Medicine Forum

Rarity Bioscience was at the Nordic Precision Medicine Forum, presenting an engaging study that highlights the latest advancements in precision oncology: ”Ultra-sensitive Monitoring of Minimal Residual Disease (MRD) for Cancer Patients, using superRCA Mutation Assays with Flow Cytometry Readout”

Read more »